优化去甲替林给药:药物基因组学、表型与标准给药策略的比较
本研究基于随机对照试验数据的药代动力学模型,比较药物基因组学、表型和标准给药(125 mg/天)三种去甲替林给药策略的准确性。结果显示,药物基因组学和表型给药均显著提高达到治疗血浆浓度的可能性并降低浓度变异性,两者间无显著差异。
要点
- 药物基因组学给药基于CYP2D6基因型,表型给药基于单次给药后血浆浓度。
- 两种个体化给药均较标准给药(125 mg/天)更易达到治疗浓度并降低变异性。
- 药物基因组学与表型给药在预测治疗浓度方面无显著差异(p=0.56)。
核心结论
- 药物基因组学和表型给药在预测去甲替林治疗血浆浓度方面比标准给药更准确。
研究设计与样本
- 基于随机对照试验数据的药代动力学建模研究,比较三种给药策略。
- 建立群体药代动力学模型以评估表型给药建议。
主要发现
- 药物基因组学给药较标准给药显著增加达到治疗浓度的可能性(χ2(1)=8.0,p=0.01)。
- 表型给药较标准给药显著增加达到治疗浓度的可能性(χ2(1)=5.3,p=0.02)。
- 两种个体化给药策略间预测治疗浓度无显著差异(χ2(1)=0.33,p=0.56)。
- 两种个体化给药均降低血浆浓度变异性。
关键数值与推荐
- 标准给药剂量为125 mg/天。
- 药物基因组学给药依据CYP2D6基因型。
- 表型给药依据单次去甲替林给药后测定的血浆浓度。
临床怎么用
- 可考虑采用药物基因组学或表型给药策略优化去甲替林剂量以提高早期达标率。
- 两种个体化策略选择可依据临床可及性,因预测准确性无显著差异。
局限性
- 研究基于药代动力学建模而非直接临床终点。
- 需进一步研究探索模型引导精准给药在去甲替林及其他精神药物中的临床应用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: Nortriptyline, a tricyclic antidepressant, has an important role in the pharmacotherapy of major depressive disorder (MDD). Individualized dosing approaches, such as pharmacogenetics-based and phenotype-based dosing, may enhance early achievement of therapeutic plasma concentrations, but their comparative accuracy has not been investigated. Our objective was to compare the accuracy of three nortriptyline dosing strategies: pharmacogenetics-based, phenotype-based, and standard dosing. METHODS: Using pharmacokinetic modeling based on data from a randomized controlled trial, we assessed and compared the following dosing strategies: pharmacogenetics-based dosing depending on the cytochrome P-450 (CYP) 2D6 genotype, phenotype-based dosing determined by the plasma concentration measured after a single nortriptyline administration, and standard dosing (125 mg/day). A population pharmacokinetic model was developed to assess phenotype-based dosing recommendations. We evaluated the dosing strategies by comparing the number of participants with predicted therapeutic, subtherapeutic, and supratherapeutic plasma concentrations using Chi-squared (χ2) tests. Variability in plasma concentrations was assessed using F-tests. RESULTS: Both pharmacogenetics-based (χ2 (1) = 8.0, p = 0.01) and phenotype-based dosing (χ2 (1) = 5.3, p = 0.02) significantly increased the likelihood of achieving therapeutic plasma concentrations compared with standard dosing while reducing plasma concentration variability. No significant difference was found in the prediction of therapeutic concentrations between the two individualized dosing strategies (χ2 (1) = 0.33, p = 0.56). CONCLUSIONS: Pharmacogenetics-based and phenotype-based dosing demonstrate greater accuracy in predicting therapeutic nortriptyline plasma concentrations than standard dosing. Further research is warranted to explore the clinical application of model-informed precision dosing for nortriptyline and other psychotropic medications.
引用
- Vos CF, Coenen MJH, Ter Hark SE, et al. Optimizing Nortriptyline Dosing: A Comparison between Pharmacogenetics-Based, Phenotype-Based, and Standard Dosing. Clin Pharmacokinet. 2025. PMID: 40413686. doi:10.1007/s40262-025-01528-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。